Fresenius Medical Care AG & Co. KGaA $FMS Stock Holdings Raised by Pzena Investment Management LLC

Pzena Investment Management LLC lifted its stake in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 1.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 14,816,852 shares of the company’s stock after purchasing an additional 153,870 shares during the period. Fresenius Medical Care AG & Co. KGaA comprises about 1.3% of Pzena Investment Management LLC’s investment portfolio, making the stock its 25th biggest holding. Pzena Investment Management LLC owned about 2.52% of Fresenius Medical Care AG & Co. KGaA worth $390,128,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of FMS. TD Waterhouse Canada Inc. bought a new position in shares of Fresenius Medical Care AG & Co. KGaA in the 2nd quarter worth about $36,000. Atlantic Union Bankshares Corp acquired a new stake in Fresenius Medical Care AG & Co. KGaA during the second quarter worth about $43,000. Hantz Financial Services Inc. raised its stake in Fresenius Medical Care AG & Co. KGaA by 568.5% during the second quarter. Hantz Financial Services Inc. now owns 2,079 shares of the company’s stock worth $59,000 after acquiring an additional 1,768 shares during the period. Huntington National Bank lifted its holdings in Fresenius Medical Care AG & Co. KGaA by 219.5% in the second quarter. Huntington National Bank now owns 2,355 shares of the company’s stock worth $67,000 after acquiring an additional 1,618 shares during the last quarter. Finally, AlphaCore Capital LLC acquired a new position in Fresenius Medical Care AG & Co. KGaA in the second quarter valued at approximately $73,000. 8.37% of the stock is owned by institutional investors.

Fresenius Medical Care AG & Co. KGaA Price Performance

Shares of NYSE:FMS opened at $24.01 on Thursday. The company has a market capitalization of $13.92 billion, a PE ratio of 17.52, a price-to-earnings-growth ratio of 0.78 and a beta of 0.90. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.00 and a current ratio of 1.36. The stock has a fifty day moving average of $23.29 and a 200-day moving average of $24.47. Fresenius Medical Care AG & Co. KGaA has a one year low of $20.94 and a one year high of $30.46.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Morgan Stanley reiterated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, January 27th. The Goldman Sachs Group cut shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a report on Tuesday, January 20th. Weiss Ratings downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 5th. Truist Financial set a $28.00 target price on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Monday, January 5th. Finally, Wall Street Zen upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th. Five analysts have rated the stock with a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, Fresenius Medical Care AG & Co. KGaA presently has an average rating of “Reduce” and a consensus target price of $28.00.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.